Tempus AI Extends AstraZeneca Partnership With $200 Million Five-Year Commitment

Tempus AI amended its agreement with AstraZeneca, securing a $200 million five-year commitment, with a minimum of $32 million annually. The deal extends through 2031, with a possible one-year extension if commitments aren't met. AstraZeneca must pay any shortfall if terminated early, according to the company's SEC filing.

Original reporting
Published Nov 18, 2026, 1:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 1:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tempus AI Extends AstraZeneca Partnership With $200 Million Five-Year Commitment — source image
Decision brief

The 30-second read

$TEMBullishHigh
01

Why it matters

The $200 million commitment is a material revenue boost, likely to be reflected in Tempus AI's near‑term valuation.

02

Market read

First disclosure of a sizable pharma partnership for Tempus AI, creating immediate trading interest.

03

What to watch

The agreement includes a penalty clause that could affect cash flow if AstraZeneca terminates early.

Relevance 7/10Novelty 9/10Timing: today

Background

Tempus AI provides AI‑driven clinical data platforms; AstraZeneca is a major pharma client.

Company-level read

Ticker impact

$TEMBullishHigh confidence
Context

Tempus AI announced a $200 million five‑year partnership extension with AstraZeneca, adding a minimum $32 million annual spend.

Expected impact

upward pressure as investors price in the additional $200 million of committed revenue

Evidence & confidence

The deal size is material for Tempus AI and represents the first public disclosure, which typically triggers a short‑term price rally.

Market effects

Strengthens the biotech data‑analytics sector by highlighting pharma partnerships.

May boost sentiment for US‑listed health‑tech stocks.

Limited to investors tracking pharma‑tech collaborations.

Counterpoint

If AstraZeneca reduces spend later, the partnership could underperform expectations.

Key entities

  • Tempus AI, Inc.

    US‑listed provider of AI‑enabled clinical data solutions.

  • AstraZeneca

    Global pharmaceutical company entering a five‑year partnership.

Related articles

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$AZNMed

Myasthenia Gravis Treatment Klygefa Wins FDA Approval as a Weekly C5 Inhibitor Shot Adults Inject at Home

The FDA approved AstraZeneca's Klygefa (gefurulimab-gaks) for treating adults with acetylcholine receptor antibody-positive generalized myasthenia gravis. The weekly self-injected C5 inhibitor showed improvement in daily-living scores over 26 weeks in a phase 3 trial. AstraZeneca claims it's the first dual-binding nanobody C5 inhibitor, but other C5 inhibitors exist. The drug carries a meningococcal infection risk, requiring vaccination before use.